Cargando…

A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy

von Hippel–Lindau (VHL) disease is an autosomal dominant hereditary disease with benign and malignant tumors occurring in various organs including the kidneys. In patients with renal cell carcinoma (RCC) lesions in both kidneys, it is difficult to determine the treatment strategy. We report a case o...

Descripción completa

Detalles Bibliográficos
Autores principales: Akioka, Takahiro, Terada, Naoki, Takamori, Hiroki, Kamimura, Toshio, Mukai, Shoichiro, Kamoto, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579142/
https://www.ncbi.nlm.nih.gov/pubmed/34786348
http://dx.doi.org/10.1016/j.eucr.2021.101925
_version_ 1784596381283909632
author Akioka, Takahiro
Terada, Naoki
Takamori, Hiroki
Kamimura, Toshio
Mukai, Shoichiro
Kamoto, Toshiyuki
author_facet Akioka, Takahiro
Terada, Naoki
Takamori, Hiroki
Kamimura, Toshio
Mukai, Shoichiro
Kamoto, Toshiyuki
author_sort Akioka, Takahiro
collection PubMed
description von Hippel–Lindau (VHL) disease is an autosomal dominant hereditary disease with benign and malignant tumors occurring in various organs including the kidneys. In patients with renal cell carcinoma (RCC) lesions in both kidneys, it is difficult to determine the treatment strategy. We report a case of VHL disease with RCC treated via partial nephrectomy after 6 months of axitinib therapy. Then, the patient continued to receive low-dose axitinib therapy without any signs of tumor progression for 3 years after surgery. Axitinib combined with surgery might be a treatment option for patients with VHL disease harboring bilateral RCC.
format Online
Article
Text
id pubmed-8579142
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85791422021-11-15 A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy Akioka, Takahiro Terada, Naoki Takamori, Hiroki Kamimura, Toshio Mukai, Shoichiro Kamoto, Toshiyuki Urol Case Rep Oncology von Hippel–Lindau (VHL) disease is an autosomal dominant hereditary disease with benign and malignant tumors occurring in various organs including the kidneys. In patients with renal cell carcinoma (RCC) lesions in both kidneys, it is difficult to determine the treatment strategy. We report a case of VHL disease with RCC treated via partial nephrectomy after 6 months of axitinib therapy. Then, the patient continued to receive low-dose axitinib therapy without any signs of tumor progression for 3 years after surgery. Axitinib combined with surgery might be a treatment option for patients with VHL disease harboring bilateral RCC. Elsevier 2021-10-30 /pmc/articles/PMC8579142/ /pubmed/34786348 http://dx.doi.org/10.1016/j.eucr.2021.101925 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Oncology
Akioka, Takahiro
Terada, Naoki
Takamori, Hiroki
Kamimura, Toshio
Mukai, Shoichiro
Kamoto, Toshiyuki
A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
title A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
title_full A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
title_fullStr A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
title_full_unstemmed A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
title_short A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
title_sort case of von hippel–lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579142/
https://www.ncbi.nlm.nih.gov/pubmed/34786348
http://dx.doi.org/10.1016/j.eucr.2021.101925
work_keys_str_mv AT akiokatakahiro acaseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT teradanaoki acaseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT takamorihiroki acaseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT kamimuratoshio acaseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT mukaishoichiro acaseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT kamototoshiyuki acaseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT akiokatakahiro caseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT teradanaoki caseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT takamorihiroki caseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT kamimuratoshio caseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT mukaishoichiro caseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy
AT kamototoshiyuki caseofvonhippellindaudiseasewithrenalcellcarcinomatreatedbypartialnephrectomywithpreandpostsurgicalaxitinibtherapy